Empowering the Future of Live Biotherapeutics: Eubacterium limosum based Microbiome Therapeutic Research Service
The landscape of modern medicine is undergoing a paradigm shift, moving from systemic chemical interventions to the precision of Live Biotherapeutic Products (LBPs). At the heart of this revolution lies the human gut microbiome, a complex ecosystem whose influence extends far beyond digestion. Among the "next-generation" of beneficial microbes, Eubacterium limosum has emerged as a powerhouse of metabolic flexibility and therapeutic potential. As a premier Contract Research Organization (CRO) specializing in preclinical microbiome research, Creative Biolabs offers a comprehensive suite of services and high-quality products designed to accelerate your E. limosum research from bench to bedside.
Overview: The Resurgence of Eubacterium limosum
Eubacterium limosum is a Gram-positive, non-spore-forming, obligate anaerobic bacterium belonging to the Eubacteriaceae family. It is a key member of the healthy human gut microbiota, known for its unique ability to utilize a wide range of C1 substrates (such as methanol, H2/CO2, and formate) through the Wood–Ljungdahl pathway. Beyond its fascinating metabolism, E. limosum is a "metabolic engineer" of the gut. It produces Short-Chain Fatty Acids (SCFAs), specifically acetate and butyrate, which are essential for gut barrier integrity and immune regulation. Recent research has highlighted its enrichment in centenarians and its role in preventing "inflammaging," marking it as a top-tier candidate for next-generation probiotics and therapeutic interventions.
Our Comprehensive Preclinical Services
As a specialized CRO, we provide the infrastructure and expertise required to navigate the complexities of Live Biotherapeutic development.
In Vitro Research Services
Strain Characterization: Full genomic sequencing, phenotypic profiling, and metabolic flux analysis.
Genetic Engineering: Utilizing advanced gene editing and recombineering systems for markerless gene knockouts or the creation of "designer" strains with enhanced metabolite production.
Co-culture Assays: Investigating interactions between E. limosum and other gut commensals or human intestinal cell lines (e.g., Caco-2).
Research Application: Targeting Diseases with Precision
Current research is rapidly expanding the therapeutic horizons for E. limosum. Our research services support the exploration of this strain across several high-impact disease areas:
E. limosum has shown remarkable efficacy in alleviating mucosal inflammation. By increasing the expression of tight junction proteins and reducing pro-inflammatory cytokines like TNF-α and IL-6, it helps restore the "leaky gut" associated with ulcerative colitis and Crohn's disease.
Recent evidence indicates that E. limosum can modulate the tumor microenvironment. Through the production of indole derivatives and the inhibition of oncogenic pathways (such as Wnt/β-catenin), it offers a novel adjunctive approach to CRC treatment.
As an acetogen, E. limosum plays a role in energy homeostasis. Preclinical studies suggest that its presence correlates with improved insulin sensitivity and glucose metabolism, making it a prime candidate for managing metabolic disorders. One of the most exciting frontiers is its role in the Carnitine-TMAO pathway. By demethylating carnitine before it can be converted into the pro-atherogenic trimethylamine (TMA) by other bacteria, E. limosum acts as a "metabolic filter" to protect against atherosclerosis.
4. The Gut-Brain Axis
By producing neuroactive metabolites and SCFAs, E. limosum is being investigated for its influence on mood, cognition, and neuroinflammation.
Frequently found in high abundance in centenarians, this strain is being researched for its ability to mitigate age-related systemic inflammation, potentially serving as a biomarker or therapeutic for healthy aging.
Our Advantages: Why Choose Our CRO?
Anaerobic Expertise
Our state-of-the-art facilities are equipped with specialized anaerobic chambers and gassing stations, ensuring the viability of strict anaerobes like E. limosum.
End-to-End Solutions
From initial strain discovery and genetic optimization to complex in vivo efficacy testing, we handle every stage of preclinical development.
Regulatory Readiness
Our data packages are designed to meet the rigorous standards for Live Biotherapeutic Products.
Scientific Partnership
We don't just provide data; our team of microbiologists and toxicologists acts as your intellectual partners to solve complex research challenges.
The therapeutic potential of Eubacterium limosum is no longer a matter of speculation but a frontier of active, data-driven research. From its role in suppressing intestinal inflammation to its emerging status as an oncology-supportive microbe, this strain represents a cornerstone of the next generation of biotherapeutics. Our mission is to provide the scientific community with the tools, data, and insights needed to transform this potential into tangible cures. By combining deep microbiological expertise with world-class preclinical infrastructure, we empower your research to move faster, safer, and further.
Is Eubacterium limosum safe for human consumption?
As a common commensal found in healthy adults and infants, it has a strong safety profile. However, for therapeutic use, it must undergo rigorous toxicology and "Qualified Presumption of Safety" (QPS) assessments, which our service provides.
Can you help with the large-scale fermentation of this strain?
Yes, we offer fermentation optimization services to determine the best carbon sources (e.g., methanol, CO2) and conditions for high-density growth and metabolite yield.
Do you offer custom genetic modifications for E. limosum?
Absolutely. We have developed a proprietary recombineering system specifically for E. limosum that allows for precise, scarless genomic modifications.
How does E. limosum differ from standard probiotics like Lactobacillus?
Unlike many Lactobacillus strains which are transient, E. limosum is a core anaerobe with unique acetogenic and demethylation capabilities, allowing it to target metabolic and cardiovascular pathways that traditional probiotics cannot.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
